Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 6/20 | 0.52 |
| ▸ | ADCY6 | O43306 | 4/20 | 0.52 |
| ▸ | ADCY3 | O60266 | 4/20 | 0.52 |
| ▸ | ADCY9 | O60503 | 4/20 | 0.52 |
| ▸ | ADCY5 | O95622 | 4/20 | 0.52 |
| ▸ | ADCY8 | P40145 | 4/20 | 0.52 |
| ▸ | ADCY7 | P51828 | 4/20 | 0.52 |
| ▸ | ADCY2 | Q08462 | 4/20 | 0.52 |
| ▸ | ADCY1 | Q08828 | 4/20 | 0.52 |
| ▸ | ADCY4 | Q8NFM4 | 4/20 | 0.52 |
| ▸ | F11 | P03951 | 13/20 | 0.40 |
| ▸ | KLKB1 | P03952 | 3/20 | 0.40 |
| ▸ | KLK1 | P06870 | 6/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.38 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13494434 | 1.00 | GCGR (0.52) | GCGRADCY6ADCY3ADCY9ADCY5 | |
| SCHEMBL13494604 | 0.91 | GCGR (0.48) | GCGRADCY6ADCY3ADCY9ADCY5 | |
| SCHEMBL20767742 | 0.91 | GCGR (0.48) | GCGRADCY6ADCY3ADCY9ADCY5 | |
| SCHEMBL14659433 | 0.91 | GCGR (0.48) | GCGRADCY6ADCY3ADCY9ADCY5 | |
| SCHEMBL20868519 | 0.87 | GCGR (0.55) | GCGRADCY6ADCY3ADCY9ADCY5 | |
| SCHEMBL20854837 | 0.87 | GCGR (0.55) | GCGRADCY6ADCY3ADCY9ADCY5 | |
| SCHEMBL20495553 | 0.87 | GCGR (0.55) | GCGRADCY6ADCY3ADCY9ADCY5 | |
| SCHEMBL13494451 | 0.87 | GCGR (0.55) | GCGRADCY6ADCY3ADCY9ADCY5 | |
| SCHEMBL17338906 | 0.87 | GCGR (0.55) | GCGRADCY6ADCY3ADCY9ADCY5 | |
| SCHEMBL13494455 | 0.87 | GCGR (0.55) | GCGRADCY6ADCY3ADCY9ADCY5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352321-B2 | Glucagon antagonists | METABASIS THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-11352321-B2 | Glucagon antagonists | METABASIS THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20190330144-A1 | GLUCAGON ANTAGONISTS | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2019-10-31 | — | — | US | disclosed |
| US-20190330144-A1 | GLUCAGON ANTAGONISTS | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2019-10-31 | — | — | US | disclosed |
| US-20190099391-A1 | Glucagon Antagonists | LIGAND PHARMACEUTICALS, INC. (US) | 2019-04-04 | — | — | US | disclosed |
| US-20190099391-A1 | Glucagon Antagonists | LIGAND PHARMACEUTICALS, INC. (US) | 2019-04-04 | — | — | US | disclosed |
| US-10221130-B2 | Glucagon antagonists | METABASIS THERAPEUTICS, INC. (US) | 2019-03-05 | — | — | US | disclosed |
| EP-3153501-B1 | GLUCAGON ANTAGONISTS | METABASIS THERAPEUTICS INC (US) | 2018-11-28 | — | — | EP | disclosed |
| US-10076504-B2 | Glucagon antagonists | LIGAND PHARMACEUTICALS, INC. | 2018-09-18 | — | — | US | disclosed |
| US-20180022695-A1 | GLUCAGON ANTAGONISTS | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2018-01-25 | — | — | US | disclosed |
| EP-3153501-A1 | GLUCAGON ANTAGONISTS | Metabasis Therapeutics, Inc. (US) | 2017-04-12 | — | — | EP | disclosed |
| EP-3153501-A1 | GLUCAGON ANTAGONISTS | Metabasis Therapeutics, Inc. (US) | 2017-04-12 | — | — | EP | disclosed |
| EP-2799428-B1 | Glucagon antagonists | METABASIS THERAPEUTICS INC (US) | 2016-11-16 | — | — | EP | disclosed |
| US-20150087680-A1 | GLUCAGON ANTAGONISTS | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2015-03-26 | — | — | US | disclosed |
| US-8907103-B2 | Glucagon antagonists | METABASIS THERAPEUTICS, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| EP-2799428-A2 | Glucagon antagonists | Metabasis Therapeutics, Inc. (US) | 2014-11-05 | — | — | EP | disclosed |
| EP-2326618-B1 | GLUCAGON ANTAGONISTS | METABASIS THERAPEUTICS INC (US) | 2014-10-15 | — | — | EP | disclosed |
| US-20130030029-A1 | Glucagon Antagonists | METABASIS THERAPEUTICS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| EP-2326618-A1 | GLUCAGON ANTAGONISTS | Metabasis Therapeutics, Inc. (US) | 2011-06-01 | — | — | EP | disclosed |
| WO-2010019830-A1 | GLUCAGON ANTAGONISTS | METABASIS THERAPEUTICS, INC. (US) | 2010-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130030029-A1 | Glucagon Antagonists | GLP1R, GCG, GCGR | GCGR 3/4885ADCY6 417/4885ADCY3 269/4885 |
| US-20190330144-A1 | GLUCAGON ANTAGONISTS | GLP1R, GCG, GCGR | GCGR 3/4885ADCY6 417/4885ADCY3 269/4885 |
| US-20190099391-A1 | Glucagon Antagonists | GLP1R, GCG, GCGR | GCGR 3/4885ADCY6 519/4885ADCY3 273/4885 |
| US-10076504-B2 | Glucagon antagonists | GLP1R, GCG, GCGR | GCGR 3/4885ADCY6 519/4885ADCY3 273/4885 |
| US-11352321-B2 | Glucagon antagonists | GLP1R, GCG, GCGR | GCGR 3/4885ADCY6 417/4885ADCY3 269/4885 |
| US-20150087680-A1 | GLUCAGON ANTAGONISTS | GLP1R, GCG, GCGR | GCGR 3/4885ADCY6 417/4885ADCY3 269/4885 |
| US-20180022695-A1 | GLUCAGON ANTAGONISTS | GLP1R, GCG, GCGR | GCGR 3/4885ADCY6 417/4885ADCY3 269/4885 |
| US-10221130-B2 | Glucagon antagonists | GLP1R, GCG, GCGR | GCGR 3/4885ADCY6 519/4885ADCY3 273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.